EA7211: A Randomized Phase III Study of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)

Brief description of study

The primary objective of this study is to assess whether preoperative hemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of patients with high risk de-differentiated liposarcoma DDLPS) and leiomyosarcoma (LMS) as measured by disease-free survival.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Medical Research
  • Age: - 99 Years
  • Gender: All

TBD

Updated on 09 Mar 2024. Study ID: 855077
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center